Role of F-18-FDG-PET/CT in restaging of patients affected by gastrointestinal stromal tumours (GIST)

Nucl Med Rev Cent East Eur. 2010;13(2):76-80.

Abstract

Background: Gastrointestinal stromal tumours (GISTs) are a subset of mesenchymal tumours that represent the most common mesenchymal neoplasms of the gastrointestinal (GI) tract and account for less than 1% of all gastrointestinal tumours.

Material and methods: We retrospectively evaluated 19 patients (6 females and 13 males; median age: 61 years ± 15 standard deviation) affected by GIST histologically documented after surgical intervention or biopsy.

Results: F18-FDG-PET/CT had identified pathologic uptakes and was considered positive for neoplastic tissue in 10 patients (53%) and negative in 9 (47%), in concordance with radiological findings.

Conclusions: F18-FDG-PET/CT is a feasible, reliable, and accurate method to restage patients affected by previously histologically confirmed GIST, also in the absence of a staging study.

MeSH terms

  • Benzamides
  • Feasibility Studies
  • Female
  • Fluorodeoxyglucose F18*
  • Gastrointestinal Stromal Tumors / diagnosis*
  • Gastrointestinal Stromal Tumors / drug therapy
  • Gastrointestinal Stromal Tumors / pathology*
  • Gastrointestinal Stromal Tumors / surgery
  • Humans
  • Imatinib Mesylate
  • Male
  • Middle Aged
  • Neoplasm Staging / methods*
  • Piperazines / therapeutic use
  • Positron-Emission Tomography*
  • Pyrimidines / therapeutic use
  • Reproducibility of Results
  • Retrospective Studies
  • Tomography, X-Ray Computed*

Substances

  • Benzamides
  • Piperazines
  • Pyrimidines
  • Fluorodeoxyglucose F18
  • Imatinib Mesylate